Technical knowledge alone is not enough for pharmaceutical professionals
Pharmaceutical professionals must develop wider commercial and business skills if they want to continue to secure the top jobs, according to NonStop Recruitment.
The specialist pharmaceutical recruitment firm warned that as firms across the world are making significant cuts, professionals must go out of their way to develop wider skill sets or face falling behind their rivals in the job market. This follows on from reports that Merck has made over 36,000 professionals — around half of its workforce — redundant over the past 5 years and plans to reduce its headcount even further.
Abid Kanji, Associate Director at NonStop Recruitment commented: “The sector has faced numerous challenges over the past few years and some firms have, and continue to be, forced into making cuts in order to remain afloat. What this means for professionals is that they have to develop much wider skill sets to secure the top jobs, of which there are now far fewer. It’s not enough just to have the technical knowledge anymore — firms will expect that as a prerequisite — now they’re looking for that understanding combined with more developed commercial and general business skills.”
“This isn’t just limited to the pharmaceutical sector; it’s a trend that can be seen across the entire business arena. Organisations now want professionals who are much more rounded than in the past and are able to identify potential commercial opportunities even if this isn’t necessarily in their remit. The spread of M&A activity has also meant firms are interested in professionals with skills in managing external partnerships and regulatory affairs. Those who fail to build at least some of these qualities and only look to develop their direct market knowledge are likely to struggle when it comes to looking for a new role as they may find the market has left them behind.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.